This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations. However, several limitations remain, including those associated with the time-consuming and highly personalized manufacturing of autologous CAR-Ts. Technologies to establish "off-the-shelf" allogeneic CAR-Ts with low alloreactivity are currently being developed, with a strong focus on gene-editing technologies. Although these technologies have many advantages, they have also strong limitations, including double-strand breaks in the DNA with multiple associated safety risks as well as the lack of modulation. As an alternative, non-gene-editing technologies provide an interesting approach to support the development of allogeneic CAR-Ts in the future, with possibilities of fine-tuning gene expression and easy development. Here, we will review the different ways allogeneic CAR-Ts can be manufactured and discuss which technologies are currently used. The biggest hurdles for successful therapy of allogeneic CAR-Ts will be summarized, and finally, an overview of the current clinical evidence for allogeneic CAR-Ts in comparison to its autologous counterpart will be given.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10814647 | PMC |
| http://dx.doi.org/10.3390/cells13020146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Translational PK-PD model for in vivo CAR-T-cell therapy delivered using CAR mRNA-loaded polymeric nanoparticle vector.
Clin Transl Sci
December 2024
Oncology Cell Therapy and Therapeutic Area Unit, Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Article Synopsis
- Autologous CAR T-cell therapy shows great promise but faces barriers like cost and logistical issues, along with challenges in allogeneic therapies.
- A new method using CAR mRNA in nanoparticles aims to create temporary CAR expression on T-cells, though it may require multiple doses, raising concerns about affordability and patient commitment.
- We developed a PK-PD model to explain transient CAR expression following nanoparticle treatment, which could help optimize dosing and ultimately support the transition from lab research to real-world therapy.
Recent updates on allogeneic CAR-T cells in hematological malignancies.
Cancer Cell Int
September 2024
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Article Synopsis
- * Allogeneic CAR-T cell therapies (allo-CAR-Ts) are being explored as an alternative to autologous therapies, showing promising results in early clinical trials, yet facing challenges like graft-versus-host disease (GvHD) and immune rejection.
- * The success of allo-CAR-Ts depends on factors such as the origin of the starter cells and gene editing techniques, and research is ongoing to address these challenges and maximize their potential for treating hematological malignancies.
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.
Int J Mol Sci
July 2024
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food and Drug Administration (FDA). Significant barriers to the effectiveness of CAR-T therapy include cytokine release syndrome (CRS), neurotoxicity in the case of Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), antigen escape, modest antitumor activity, restricted trafficking, limited persistence, the immunosuppressive microenvironment, and senescence and exhaustion of CAR-Ts.
View Article and Find Full Text PDFAllogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Cells
January 2024
Celyad Oncology SA, 1435 Mont-Saint-Guibert, Belgium.
This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations. However, several limitations remain, including those associated with the time-consuming and highly personalized manufacturing of autologous CAR-Ts. Technologies to establish "off-the-shelf" allogeneic CAR-Ts with low alloreactivity are currently being developed, with a strong focus on gene-editing technologies.
View Article and Find Full Text PDFThe Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Biology (Basel)
November 2023
Research Department of Haematology, Cancer Institute, University College London, Paul O'Gorman Building, London WCIE 6DD, UK.
Adoptive cell therapy (ACT) has transformed the treatment landscape for cancer and infectious disease through the investigational use of chimeric antigen receptor T-cells (CAR-Ts), tumour-infiltrating lymphocytes (TILs) and viral-specific T-cells (VSTs). Whilst these represent breakthrough treatments, there are subsets of patients who fail to respond to autologous ACT products. This is frequently due to impaired patient T-cell function or "fitness" as a consequence of prior treatments and age, and can be exacerbated by complex manufacturing protocols.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!